ACT 709478

Synopsis, Chemistry

DEVELOPMENTS

2 Drug(s) in Development

2 Drug(s) in Development

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Act-709478, 1838651-58-3, 3z7u1u8z9e, N-(1-((5-cyanopyridin-2-yl)methyl)-1h-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)-phenyl)acetamide, Benzeneacetamide, n-[1-[(5-cyano-2-pyridinyl)methyl]-1h-pyrazol-3-yl]-4-[1-(trifluoromethyl)cyclopropyl]-, N-(1-((5-cyanopyridin-2-yl)methyl)pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide

Molecular Formula

C₂₂H₁₈F₃N₅O

Molecular Weight

425.4 g/mol

InChI Key

LSYANGLAZUZYFX-UHFFFAOYSA-N

FDA UNII

3Z7U1U8Z9E

ACT-709478 is under investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients).

1 2D Structure

ACT-709478

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[1-[(5-cyanopyridin-2-yl)methyl]pyrazol-3-yl]-2-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetamide

2.1.2 InChI

InChI=1S/C22H18F3N5O/c23-22(24,25)21(8-9-21)17-4-1-15(2-5-17)11-20(31)28-19-7-10-30(29-19)14-18-6-3-16(12-26)13-27-18/h1-7,10,13H,8-9,11,14H2,(H,28,29,31)

2.1.3 InChI Key

LSYANGLAZUZYFX-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CC1(C2=CC=C(C=C2)CC(=O)NC3=NN(C=C3)CC4=NC=C(C=C4)C#N)C(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

3Z7U1U8Z9E

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Act-709478

2. N-(1-((5-cyanopyridin-2-yl)methyl)pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide

2.3.2 Depositor-Supplied Synonyms

1. Act-709478

2. 1838651-58-3

3. 3z7u1u8z9e

4. N-(1-((5-cyanopyridin-2-yl)methyl)-1h-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)-phenyl)acetamide

5. Benzeneacetamide, N-[1-[(5-cyano-2-pyridinyl)methyl]-1h-pyrazol-3-yl]-4-[1-(trifluoromethyl)cyclopropyl]-

6. N-(1-((5-cyanopyridin-2-yl)methyl)pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide

7. N-[1-[(5-cyanopyridin-2-yl)methyl]pyrazol-3-yl]-2-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetamide

8. Unii-3z7u1u8z9e

9. Chembl4217292

10. Schembl17316866

11. Bcp30302

12. Ex-a3130

13. Bdbm50452245

14. Akos037648975

15. Act 709478

16. Bs-16157

17. Hy-112723

18. Cs-0062884

19. Act709478; Act 709478

20. D80992

2.4 Create Date

2016-02-23

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₁₈F₃N₅O
Molecular Weight	425.4 g/mol
XLogP3	3.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	6
Exact Mass	425.14634470 g/mol
Monoisotopic Mass	425.14634470 g/mol
Topological Polar Surface Area	83.6 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	693
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Calcium Channel Blockers

A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)